Amgen Reports Long-Term XGEVA Data for Denosumab in Bone Metastases Prevention

Amgen today presented long-term data for XGEVA (denosumab) in patients with bone metastases from solid tumors. The data showed that XGEVA maintained significant reductions in skeletal-related events over long-term treatment, with the greatest benefit observed in patients with prostate cancer and breast cancer bone metastases.